trending Market Intelligence /marketintelligence/en/news-insights/trending/FCAOBQdGX6ChqgBzbb0-Xw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US FDA approves Relmada's application for antidepressant drug

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


US FDA approves Relmada's application for antidepressant drug

Relmada Therapeutics Inc. said the U.S. FDA cleared the company's investigational new drug application for d-Methadone, its novel, N-methyl-D-aspartate receptor antagonist.

D-Methadone is a rapid acting, oral agent for the treatment of depression, neuropathic pain and other potential central nervous system pathological conditions.

The company can now advance the development program for d-Methadone to a phase 2a proof-of-concept clinical study in patients with treatment-resistant depression.